Cancer Immunotherapy Reaches A Tipping Point
This article was originally published in Start Up
Now that it is clear the immune system can kill cancer, all kinds of companies are obsessed with the idea. Start-ups are tailoring business models to divergent technologies and market dynamics.
You may also be interested in...
The biotech’s personalized vaccine shows it can reduce the risk of melanoma recurrence by 50% in the per-treatment population, but Phase III will need to demonstrate a similar benefit in an intent-to-treat population.
Cancer immunotherapy's potential payoff is big enough that acknowledged competitors are settling disputes, potential competitors are forging alliances, and start-ups like their chances of success. Profiles of Annias Immunotherapeutics, Costanoan Immunotherapies, and Unum Therapeutics.
Privately-owned Swiss firm preparing for its first solo launch in the US by doubling its sales force.